Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - cefotaxime sodium, quantity: 1048 mg (equivalent: cefotaxime, qty 1000 mg) - injection, powder for - excipient ingredients: - cefotaxime injection is indicated for the treatment of the following types of infection when caused by susceptible micro-organisms. infections of the respiratory tract (upper and lower). infections of the urinary tract. septicaemia - concomitant therapy with an aminoglycoside may be instituted prior to isolation of the causative organism. intra-abdominal infection. gonorrhoea (including gonorrhoea caused by beta-lactamase producing strains of n. gonorrhoeae.) ear, nose and throat (ent) infections. skin and skin structure infections. bone and joint infections. meningitis - cefotaxime should be combined with an appropriate alternative antibiotic (ampicillin, chloramphenicol or penicillin g) for initial therapy in children, (excluding neonates), pending the availability of culture and sensitivity results. in adults the empirical use of cefotaxime should be restricted to patients suspected of having meningitis caused by gram-negative enteric bacilli. cefotaxime injection may be used for the prevention of post-operative infection in obstetric surgery, vaginal and abdominal hysterectomy and biliary surgery. in serious cases, cefotaxime injection may be used, if considered appropriate, before the results of sensitivity tests become available. the emergence of resistance to cefotaxime may complicate treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - cefotaxime sodium, quantity: 524 mg (equivalent: cefotaxime, qty 500 mg) - injection, powder for - excipient ingredients: - cefotaxime hexal injection is indicated for the treatment of the following types of infection when caused by susceptible micro-organisms. infections of the respiratory tract (upper and lower). infections of the urinary tract. septicaemia - concomitant therapy with an aminoglycoside may be instituted prior to isolation of the causative organism. intra-abdominal infection. gonorrhoea (including gonorrhoea caused by beta-lactamase producing strains of n. gonorrhoeae.) ear, nose and throat (ent) infections. skin and skin structure infections. bone and joint infections. meningitis - cefotaxime should be combined with an appropriate alternative antibiotic (ampicillin, chloramphenicol or penicillin g) for initial therapy in children, (excluding neonates), pending the availability of culture and sensitivity results. in adults the empirical use of cefotaxime should be restricted to patients suspected of having meningitis caused by gram-negative enteric bacilli. cefotaxime hexal injection may be used for the prevention of post-operative infection in obstetric surgery, vaginal and abdominal hysterectomy and biliary surgery. in serious cases, cefotaxime hexal injection may be used, if considered appropriate, before the results of sensitivity tests become available. the emergence of resistance to cefotaxime may complicate treatment.

Israel - English - Ministry of Health

a.l. medi-market ltd. - cefotaxime as sodium - powder for solution for inj/inf - cefotaxime as sodium 1 g/vial - cefotaxime - imetoxim 1 gr is indicated in the treatment of the following infections either before the infecting organism has been identified or when caused by bacteria of established sensitivity. septicaemiasrespiratory tract infections such as acute and chronic bronchitis, bacterial pneumonia, infected bronchiectasis, lung abscess and post-operative chest infections. urinary tract infections such as acute and chronic pyelonephritis, cystitis and asymptomatic bacteriuria. soft-tissue infections such as cellulitis, peritonitis and wound infections. bone and joint infections such as osteomyelitis, septic arthritis. obstetric and gynaecological infections such as pelvic inflammatory disease. gonorrhoea particularly when penicillin has failed or is unsuitable. other bacterial infections such as meningitis and other sensitive infections suitable for parenteral antibiotic therapy prophylaxis: prophylaxis of infections in patients with reduced resistance. pre-operative prophylaxis in patients who are at increased risk from infection.

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - cefotaxime sodium - pdr for soln inj/inf - 2 grams

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - cefotaxime sodium - pdr for soln for injection - 500 milligram - third-generation cephalosporins

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - cefotaxime sodium - pdr for soln for injection - 1 grams - third-generation cephalosporins

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

wockhardt uk ltd - cefotaxime sodium - powder for solution for injection - 1gram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

wockhardt uk ltd - cefotaxime sodium - powder for solution for injection - 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

wockhardt uk ltd - cefotaxime sodium - powder for solution for injection - 2gram

United States - English - NLM (National Library of Medicine)

wockhardt limited - cefotaxime sodium (unii: 258j72s7tz) (cefotaxime - unii:n2gi8b1gk7) - cefotaxime sodium 500 mg in 1 ml - - lower respiratory tract infections , including pneumonia, caused by streptococcus pneumoniae (formerly diplococcus pneumoniae ), streptococcus pyogenes * (group a streptococci) and other streptococci (excluding enterococci, e.g., enterococcus faecalis ), staphylococcus aureus (penicillinase and non-penicillinase producing), escherichia coli , klebsiella species , haemophilus influenzae (including ampicillin resistant strains), haemophilus parainfluenzae, proteus mirabilis, serratia marcescens*, enterobacter species, indole positive proteus and pseudomonas species (including p. aeruginosa ). - genitourinary infections. urinary tract infections caused by enterococcus species, staphylococcus epidermidis, staphylococcus aureus* , (penicillinase and non-penicillinase producing), citrobacter species, enterobacter species, escherichia coli , klebsiella  species, proteus mirabilis, proteus vulgaris*, providencia stuartii, morganella morganii*, providencia rettgeri*, serratia marcescens and pseudomonas s